

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



09th August 2019

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Scrip Code : 524518

Name of Scrip : KREBSBIO

Dear Sir / Madam,

Sub : Outcome of Board Meeting

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [“SEBI LODR Regulations”], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 09th August 2019 :

- (a) The unaudited financial results for the quarter ended 30th June 2019 along with the Limited Review Report thereon (Enclosed herewith).
- (b) Re-appointment of Mr. G V L Prasad (DIN: 00017081) as Independent Director of the Company w.e.f. 1st January 2020 for a period of 5 years.
- (c) Re-appointment of Mrs. Tangirala Malati (DIN 07094957) as Independent Director of the Company w.e.f. 11th March 2020 for a period of 5 years.
- (d) Re-appointment of Mr. Satish Khivsara (DIN 07244464) as Independent Director of the Company w.e.f 1st April 2020 for a period of 5 years.
- (e) Re-appointment of M/s Suryanarayana & Suresh, Chartered Accountants as Internal Auditors of the Company for the financial year 2019-20.
- (f) Notice of the 27th Annual General Meeting of the members of the Company scheduled to be held on 25th September 2019 along with the Board's Report and annexures thereto.
- (g) Resignation of Ms. Haritha Varanasi as Company Secretary of the Company.
- (h) Appointment of Ms. Taruni Banda as Company Secretary of the Company.



Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



Kindly note that the meeting was commenced at 03:15 PM and concluded at 05:10 PM

You are requested to take note of the above.

Thanking you,

Yours faithfully,
For Krebs Biochemicals & Industries Limited

Avinash Ravi
Managing Director

KREBS BIOCHEMICALS & INDUSTRIES LIMITED


CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Rs. in lacs)

Sl.No	Particulars	Quarter Ended			Year Ended
		30.06.2019 (Unaudited)	31.03.2019 (Audited)	30.06.2018 (Audited)	31.03.2019 (Audited)
	PART - 1				
1	Revenue from Operations				
	a) Net Sales / Income from Operations	301.93	851.53	654.74	3,713.27
	b) Other Operating Income	164.12	319.53	239.93	1,062.53
2	Other Income	17.81	16.22	3.00	33.06
3	Total Income from operations (1+2)	483.86	1,187.28	897.67	4,808.86
4	Expenses				
	a) Cost of Material Consumed	325.66	435.18	114.28	2,099.43
	b) Changes in Inventories of Finished goods, Work-In-Progress	(82.55)	96.31	339.21	210.93
	c) Employee Benefits Expenses	372.19	387.80	340.03	1,493.70
	d) Finance Costs	160.53	189.73	142.40	623.80
	e) Depreciation and Amortisation Expense	114.89	118.11	107.37	440.23
	f) Other Manufacturing Expenses	279.86	380.68	304.49	1,579.60
	g) Other Expenses	71.96	111.43	76.39	373.41
	Total Expenses (4)	1,242.54	1,719.24	1,424.17	6,821.10
5	Profit / (Loss) before exceptional items and tax (3±4)	(758.68)	(531.96)	(526.50)	(2,012.24)
6	Exceptional Items:				
	a) Depletion in Value of Inventory	-	-	-	-
	b) Amounts Written off/ written back	-	11.09	-	11.09
	c) Prior Period Income/(Expenditure)	-	-	-	-
	d) Profit on sale of Fixed Assets	-	-	-	-
7	Profit / (Loss) before Tax (5 ± 6)	(758.68)	(520.87)	(526.50)	(2,001.15)
8	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	-	-	-
9	Profit / (Loss) for the period (7 ± 8)	(758.68)	(520.87)	(526.50)	(2,001.15)
10	Other Comprehensive Income (OCI)				
i	Items that will not be reclassified to profit or Loss	-	(5.09)	-	0.20
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-
iii	Items that will be reclassified to profit or Loss	(33.56)	(47.53)	(26.59)	(132.26)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	(33.56)	(52.62)	(26.59)	(132.06)
11	Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)	(792.24)	(573.49)	(553.09)	(2,133.22)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1663.06	1663.06	1374.43	1663.06
13	Other Equity excluding Revaluation Reserve	-	-	-	(1,986.27)
14	Earning Per Share (of Rs.10/- each) (not Annualised)				
	a) Basic	(4.76)	(3.45)	(4.02)	(12.83)
	b) Diluted	(4.76)	(4.16)	(4.02)	(15.46)
	See accompanying notes to the Financial results				
1	The above results have been reviewed by the Audit Committee at its meeting held on 9th August 2019 and approved by the Board of Directors of the Company at its meeting held on 9th August 2019. The results are subjected to limited review by statutory auditors.				
2	The Company is operating in one segment only hence no segment results have been disclosed.				
3	The results for the quarter ended 31.03.2019 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year.				
4	The Company has received stop production order at its manufacturing unit in Vishakhapatnam district on 10th May 2019 from AP Pollution Control Board citing non compliance. This has impacted the production and resulted in lower turnover for the quarter. The Company, after complying with the directions of the Board as listed out in the stop production order, received the revocation of stop production order from AP Pollution control Board vide its letter dated 01st August,2019.				
5	The Company has adopted Ind AS-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the Company.				
6	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.				
Place: Hyderabad				 Avinash Ravi Managing Director DIN : 01616152	
Date: 09.08.2019					



PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Micasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 264 0
Email : pavuluriandco@gmail.com

Limited Review Report

Review Report to


The Board of Directors,

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th June, 2019** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S

N. Rajesh
(CA. N. RAJESH)
PARTNER
M.No: 223169
UDIN # 19223169AAAABE8538



Place: Hyderabad
Date: 09.08.2019